Inferring causal genomic alterations in breast cancer using gene expression data

BMC Systems Biology

Volumn 5, Issue , 2011, Pages

  Tran, Linh M ^a,b   Zhang, Bin ^a,b   Zhang, Zhan ^b   Zhang, Chunsheng ^b   Xie, Tao ^b   Lamb, John R ^b   Dai, Hongyue ^b   Schadt, Eric E ^a,b,c   Zhu, Jun ^a,b  

^a SAGE BIONETWORKS   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c PACIFIC BIOSCIENCES   (United States)

Author keywords

Breast cancer; Copy number variation; Gene regulatory networks; Oncogenes

Indexed keywords

SMALL INTERFERING RNA;

ALGORITHM; ARTICLE; BAYES THEOREM; BREAST TUMOR; COPY NUMBER VARIATION; FEMALE; GENE REGULATORY NETWORK; GENETICS; HUMAN; METHODOLOGY; MUTATION; SYSTEMS BIOLOGY; TUMOR GENE;

ALGORITHMS; BAYES THEOREM; BREAST NEOPLASMS; DNA COPY NUMBER VARIATIONS; FEMALE; GENE REGULATORY NETWORKS; GENES, NEOPLASM; HUMANS; MUTATION; RNA, SMALL INTERFERING; SYSTEMS BIOLOGY;

EID: 79960888804     PISSN: None     EISSN: 17520509     Source Type: Journal    
DOI: 10.1186/1752-0509-5-121     Document Type: Article

References (55)

1. Hebbring SJ, Moyer AM, Weinshilboum RM. Sulfotransferase gene copy number variation: pharmacogenetics and function. Cytogenet Genome Res 2008, 123(1-4):205-10. 10.1159/000184710, 2920188, 19287157.
2. Mullighan CG, Downing JR. Genome-wide profiling of genetic alterations in acute lymphoblastic leukemia: recent insights and future directions. Leukemia 2009,
3. Overdevest JB, Theodorescu D, Lee JK. Utilizing the molecular gateway: the path to personalized cancer management. Clin Chem 2009, 55(4):684-971. 10.1373/clinchem.2008.118554, 19246616.
4. Swanton C, Caldas C. Molecular classification of solid tumours: towards pathway-driven therapeutics. Br J Cancer 2009,
5. van 't Veer LJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415(6871):530-6. 10.1038/415530a, 11823860.
6. Wang Y, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005, 365(9460):671-9.
7. Fan C, et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006, 355(6):560-9. 10.1056/NEJMoa052933, 16899776.
8. Sotiriou C, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006, 98(4):262-72. 10.1093/jnci/djj052, 16478745.
9. Andre F, et al. Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res 2009, 15(2):441-51. 10.1158/1078-0432.CCR-08-1791, 19147748.
10. Haverty PM, et al. High-resolution genomic and expression analyses of copy number alterations in breast tumors. Genes Chromosomes Cancer 2008, 47(6):530-42. 10.1002/gcc.20558, 18335499.
11. Heidenblad M, et al. Microarray analyses reveal strong influence of DNA copy number alterations on the transcriptional patterns in pancreatic cancer: implications for the interpretation of genomic amplifications. Oncogene 2005, 24(10):1794-801. 10.1038/sj.onc.1208383, 15688027.
12. Pollack JR, et al. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci USA 2002, 99(20):12963-8. 10.1073/pnas.162471999, 130569, 12297621.
13. Hu G, et al. MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer. Cancer Cell 2009, 15(1):9-20. 10.1016/j.ccr.2008.11.013, 2676231, 19111877.
14. van 't Veer LJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415(6871):530-6. 10.1038/415530a, 11823860.
15. Miller LD, et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 2005, 102(38):13550-5. 10.1073/pnas.0506230102, 1197273, 16141321.
16. Bergamaschi A, et al. Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer 2006, 45(11):1033-40. 10.1002/gcc.20366, 16897746.
17. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature 2009, 458(7239):719-24. 10.1038/nature07943, 2821689, 19360079.
18. Torkamani A, et al. Coexpression network analysis of neural tissue reveals perturbations in developmental processes in schizophrenia. Genome Res 2010, 20(4):403-12. 10.1101/gr.101956.109, 2847743, 20197298.
19. Cerami E, et al. Automated network analysis identifies core pathways in glioblastoma. PLoS ONE 2010, 5(2):e8918. 10.1371/journal.pone.0008918, 2820542, 20169195.
20. Kulp DC, Jagalur M. Causal inference of regulator-target pairs by gene mapping of expression phenotypes. BMC Genomics 2006, 7:125. 10.1186/1471-2164-7-125, 1481560, 16719927.
21. Lum PY, et al. Elucidating the murine brain transcriptional network in a segregating mouse population to identify core functional modules for obesity and diabetes. J Neurochem 2006, 97(Suppl 1):50-62.
22. Mehrabian M, et al. Integrating genotypic and expression data in a segregating mouse population to identify 5-lipoxygenase as a susceptibility gene for obesity and bone traits. Nat Genet 2005, 37(11):1224-33. 10.1038/ng1619, 16200066.
23. Schadt EE, et al. An integrative genomics approach to infer causal associations between gene expression and disease. Nat Genet 2005, 37(7):710-7. 10.1038/ng1589, 2841396, 15965475.
24. Zhu J, et al. An integrative genomics approach to the reconstruction of gene networks in segregating populations. Cytogenet Genome Res 2004, 105(2-4):363-74. 10.1159/000078209, 15237224.
25. Zhu J, et al. Integrating large-scale functional genomic data to dissect the complexity of yeast regulatory networks. Nat Genet 2008, 40(7):854-61. 10.1038/ng.167, 2573859, 18552845.
26. Zhu J, et al. Increasing the Power to Detect Causal Associations by Combining Genotypic and Expression Data in Segregating Populations. PLoS Comput Biol 2007, 3(4):e69. 10.1371/journal.pcbi.0030069, 1851982, 17432931.
27. Yang X, et al. Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver. Genome Res 2010,
28. Sharan R, Ulitsky I, Shamir R. Network-based prediction of protein function. Mol Syst Biol 2007, 3:88. 1847944, 17353930.
29. Roodi N, et al. Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer. J Natl Cancer Inst 1995, 87(6):446-51. 10.1093/jnci/87.6.446, 7861463.
30. Bartz SR, et al. Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions. Mol Cell Biol 2006, 26(24):9377-86. 10.1128/MCB.01229-06, 1698535, 17000754.
31. Berns K, et al. A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 2004, 428(6981):431-7. 10.1038/nature02371, 15042092.
32. Jackson AL, et al. Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol 2003, 21(6):635-7. 10.1038/nbt831, 12754523.
33. Strang GN, Truong. Wavelets and Filter Banks. 1996, Wellesley, MA, USA: Wellesley-Cambrage Press.
34. Boulay PL, et al. ADP-ribosylation factor 1 controls the activation of the phosphatidylinositol 3-kinase pathway to regulate epidermal growth factor-dependent growth and migration of breast cancer cells. J Biol Chem 2008, 283(52):36425-34. 10.1074/jbc.M803603200, 2662303, 18990689.
35. Lu X, et al. In vivo dynamics and distinct functions of hypoxia in primary tumor growth and organotropic metastasis of breast cancer. Cancer Res 2010, 70(10):3905-14. 10.1158/0008-5472.CAN-09-3739, 2872139, 20442288.
36. Nakshatri H, Badve S. FOXA1 in breast cancer. Expert Rev Mol Med 2009, 11:e8.
37. Torkamani A, Schork NJ. Identification of rare cancer driver mutations by network reconstruction. Genome Res 2009, 19(9):1570-8. 10.1101/gr.092833.109, 2752121, 19574499.
38. Macarulla T, Ramos FJ, Tabernero J. Aurora kinase family: a new target for anticancer drug. Recent Pat Anticancer Drug Discov 2008, 3(2):114-22. 10.2174/157489208784638785, 18537754.
39. Mita AC, et al. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res 2008, 14(16):5000-5. 10.1158/1078-0432.CCR-08-0746, 18698017.
40. Rana S, et al. Stathmin 1: a novel therapeutic target for anticancer activity. Expert Rev Anticancer Ther 2008, 8(9):1461-70. 10.1586/14737140.8.9.1461, 18759697.
41. Peset I, Vernos I. The TACC proteins: TACC-ling microtubule dynamics and centrosome function. Trends Cell Biol 2008, 18(8):379-88. 10.1016/j.tcb.2008.06.005, 18656360.
42. Fridlyand J, et al. Breast tumor copy number aberration phenotypes and genomic instability. BMC Cancer 2006, 6:96. 10.1186/1471-2407-6-96, 1459181, 16620391.
43. Still IH, Vince P, Cowell JK. The third member of the transforming acidic coiled coil-containing gene family, TACC3, maps in 4p16, close to translocation breakpoints in multiple myeloma, and is upregulated in various cancer cell lines. Genomics 1999, 58(2):165-70. 10.1006/geno.1999.5829, 10366448.
44. Ulisse S, et al. Transforming acidic coiled-coil 3 and Aurora-A interact in human thyrocytes and their expression is deregulated in thyroid cancer tissues. Endocr Relat Cancer 2007, 14(3):827-37. 10.1677/ERC-07-0053, 2216418, 17914111.
45. Kufer TA, et al. Human TPX2 is required for targeting Aurora-A kinase to the spindle. J Cell Biol 2002, 158(4):617-23. 10.1083/jcb.200204155, 2174010, 12177045.
46. LeRoy PJ, et al. Localization of human TACC3 to mitotic spindles is mediated by phosphorylation on Ser558 by Aurora A: a novel pharmacodynamic method for measuring Aurora A activity. Cancer Res 2007, 67(11):5362-70. 10.1158/0008-5472.CAN-07-0122, 17545617.
47. Emilsson V, et al. Genetics of gene expression and its effect on disease. Nature 2008, 452(7186):423-8. 10.1038/nature06758, 18344981.
48. Zhang B, Horvath S. A general framework for weighted gene co-expression network analysis. Stat Appl Genet Mol Biol 2005, 4. Article17.
49. Xu X, et al. Quantitative proteomics study of breast cancer cell lines isolated from a single patient: discovery of TIMM17A as a marker for breast cancer. Proteomics 2010, 10(7):1374-90. 10.1002/pmic.200900380, 20198662.
50. Li J, et al. Identification of high-quality cancer prognostic markers and metastasis network modules. Nat Commun 2010, 1:34. 2972666, 20975711.
51. Akavia UD, et al. An integrated approach to uncover drivers of cancer. Cell 2010, 143(6):1005-17. 10.1016/j.cell.2010.11.013, 21129771.
52. Jornsten R, et al. Network modeling of the transcriptional effects of copy number aberrations in glioblastoma. Mol Syst Biol 2011, 7:486. 3101951, 21525872.
53. Cahan P, et al. The impact of copy number variation on local gene expression in mouse hematopoietic stem and progenitor cells. Nat Genet 2009, 41(4):430-7. 10.1038/ng.350, 2728431, 19270704.
54. Stranger BE, et al. Relative impact of nucleotide and copy number variation on gene expression phenotypes. Science 2007, 315(5813):848-53. 10.1126/science.1136678, 2665772, 17289997.
55. Hastings PJ, et al. Mechanisms of change in gene copy number. Nat Rev Genet 2009, 10(8):551-64. 10.1038/nrg2593, 2864001, 19597530.